Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C20H26O2
CAS Number:
Molecular Weight:
298.42
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
EC Number:
200-681-6
Beilstein/REAXYS Number:
1915671
MDL number:
grade
pharmaceutical primary standard
API family
norethindrone
manufacturer/tradename
USP
mp
205-206 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
[H][C@]12CCC(=O)C=C1CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@]4(O)C#C
InChI
1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
InChI key
VIKNJXKGJWUCNN-XGXHKTLJSA-N
Gene Information
human ... PGR(5241)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Norethindrone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Norethindrone Tablets
- Norethindrone Acetate Tablets
- Norethindrone and Mestranol Tablets
- Norethindrone and Ethinyl Estradiol Tablets
- Fluocinolone Acetonide Cream
- Fluoxymesterone Tablets
Biochem/physiol Actions
19-norethindrone is an oral contraceptive involved in the inhibition of cytosolic sulfotransferases (SULT).
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 1A
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Regulatory Information
涉药品监管产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
L R Wiseman et al.
Drugs & aging, 4(3), 238-256 (1994-03-01)
The combined transdermal estradiol/norethisterone therapeutic system is designed to deliver both estradiol and norethisterone into the systemic circulation at a constant rate for up to 4 days when affixed to the skin. Transdermal administration avoids hepatic first-pass metabolism, allowing therapeutic
Kristof Chwalisz et al.
Reproductive sciences (Thousand Oaks, Calif.), 19(6), 563-571 (2012-03-30)
Gonadotropin-releasing hormone agonists (GnRHa) are an effective treatment of endometriosis-associated pelvic pain. The use of hormonal add-back therapy can alleviate the hypoestrogenic symptoms associated with GnRHa therapy, while preserving therapeutic efficacy. Norethindrone acetate (NETA) is a unique progestin that has
F Z Stanczyk et al.
Contraception, 42(1), 67-96 (1990-07-01)
There is limited information on the metabolism of levonorgestrel, norethindrone and structurally related contraceptive steroids. Both levonorgestrel and norethindrone undergo extensive reduction of the alpha, beta-unsaturated ketone in ring A. Levonorgestrel also undergoes hydroxylation at carbons 2 and 16. The
H F Taitel et al.
International journal of fertility and menopausal studies, 40(4), 207-223 (1995-07-01)
Norethindrone is utilized for numerous noncontraceptive therapies, especially during the menopause. Through an analysis of the literature we have described the pharmacological profile of norethindrone and the potential therapeutic implications of low-dose therapies, with an emphasis on endometrial pathology, climacteric
Rajesh Rajput et al.
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 30(8), 680-683 (2008-09-13)
The association between the progestin-only pill used for treatment of menstrual disorders and central venous sinus thrombosis (CVST) has rarely been reported in the literature. This report describes a case of central venous sinus thrombosis following intake of norethindrone acetate
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 1469005-200MG | 04061838737182 |
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service